CardioComm Solutions, Inc. to confirm it has entered into a technology integration agreement with LiveCare Corp. ("LiveCare") and a Value-Added Reseller and Distribution Agreement with Alliance Tele-Med ("Alliance"), to provide integrated ECG monitoring through the LiveCare Link+ device and telemedicine platform. CardioComm confirms integration of their FDA and Health Canada cleared GEMS™ ECG management software, the wireless HeartCheck™ CardiBeat ECG monitor and access to the SMART Monitoring ECG reading service into the Link+ platform has been completed. Under the agreement, the GEMS™ Mobile app technology was embedded into the Link+ gateway device allowing ECGs to be transferred through the Link+ platform to the CardioComm SMART Monitoring ECG reading service. Once an ECG report is completed, the report findings are then securely transmitted to the Link+ platform and from there to the Link+ platform's remote patient monitoring teams. Through the addition of the GEMS™ technology into the Link+ gateway device, the Link+ device will be capable of recognizing multiple ECG devices with up to 12 leads of ECG recording and provide Link+ customers with more options in choosing a device of their preference. The HeartCheck™ CardiBeat will be the recommended device for remote ECG patient monitoring given its availability in Canada, the US and Europe. All recorded ECGs will be passed through CardioComm’s SMART Monitoring ECG triaging service. ECG reports confirming the presence or absence of an arrhythmia will be provided to Link+ users. The Link+ platform with ECG monitoring sales and marketing will be undertaken exclusively by Alliance with a focus on monitoring patients with or suspected to have COVID-19. Sales into the US is where the primary marketing efforts are targeted for 2021. CardioComm will see revenue from the sales of the HeartCheck™ CardiBeat ECG devices as well as from ECG triaging service fees.